Robeco Institutional Asset Management B.V. Acquires 8,833 Shares of Neurocrine Biosciences, Inc. $NBIX

Robeco Institutional Asset Management B.V. boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 8.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 116,809 shares of the company’s stock after buying an additional 8,833 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Neurocrine Biosciences were worth $16,568,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in NBIX. Basecamp Wealth Advisors LLC lifted its stake in shares of Neurocrine Biosciences by 582.9% in the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock valued at $31,000 after buying an additional 204 shares in the last quarter. Cassaday & Co Wealth Management LLC acquired a new position in shares of Neurocrine Biosciences during the first quarter valued at about $33,000. Ascentis Independent Advisors bought a new stake in shares of Neurocrine Biosciences during the first quarter worth about $40,000. SJS Investment Consulting Inc. increased its position in shares of Neurocrine Biosciences by 67.2% during the first quarter. SJS Investment Consulting Inc. now owns 341 shares of the company’s stock worth $45,000 after acquiring an additional 137 shares in the last quarter. Finally, TrinityBridge Ltd bought a new stake in shares of Neurocrine Biosciences during the second quarter worth about $45,000. 92.59% of the stock is owned by institutional investors.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, CFO Matt Abernethy sold 2,311 shares of the business’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $157.20, for a total transaction of $363,289.20. Following the sale, the chief financial officer owned 42,808 shares of the company’s stock, valued at $6,729,417.60. The trade was a 5.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Leslie V. Norwalk sold 1,250 shares of the business’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $182.01, for a total transaction of $227,512.50. Following the transaction, the director owned 1,588 shares of the company’s stock, valued at $289,031.88. This trade represents a 44.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 4,387 shares of company stock worth $720,855. Corporate insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Stock Performance

Shares of NBIX opened at $142.70 on Friday. The business has a 50-day moving average of $147.49 and a 200 day moving average of $153.80. Neurocrine Biosciences, Inc. has a fifty-two week low of $122.14 and a fifty-two week high of $186.12. The firm has a market cap of $14.51 billion, a P/E ratio of 19.79, a price-to-earnings-growth ratio of 0.63 and a beta of 0.40.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Friday, July 31st. The company reported $2.85 EPS for the quarter, beating analysts’ consensus estimates of $1.65 by $1.20. The company had revenue of $959.00 million for the quarter, compared to analysts’ expectations of $891.16 million. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. Neurocrine Biosciences’s revenue was up 39.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.65 EPS. As a group, research analysts predict that Neurocrine Biosciences, Inc. will post 7.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on NBIX shares. Needham & Company LLC restated a “buy” rating and issued a $204.00 target price on shares of Neurocrine Biosciences in a report on Friday, October 16th. Mizuho upgraded Neurocrine Biosciences to a “hold” rating in a research note on Wednesday, September 16th. Wells Fargo & Company lifted their price target on Neurocrine Biosciences from $175.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Morgan Stanley boosted their price objective on Neurocrine Biosciences from $182.00 to $183.00 and gave the stock an “equal weight” rating in a report on Friday, September 11th. Finally, UBS Group lowered their price objective on Neurocrine Biosciences from $231.00 to $214.00 and set a “buy” rating for the company in a research note on Tuesday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $201.14.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.